Skip to main content
Search form
Home
About Heron
Company Overview
IITs, Grants, Sponsorships, and Contributions
Management
Board of Directors
Compliance
Contact Us
Careers
Our Focus
Our Mission
Our Technologies
About the 505(
b
)(2) Regulatory Pathway
Product Portfolio
Pipeline
SUSTOL
®
CINVANTI
®
HTX-011 (ZYNRELEF™)
HTX-034
Patient/Investigator Resources
About Chemotherapy-Induced Nausea and Vomiting (CINV)
About Pain Management
Scientific Posters and Presentations
Publications
Investor Resources
Investor Resources Home
News, Events and Presentations
News Releases
Events and Webcasts
Corporate Presentations
SEC Filings
Stock Information
Stock Quote
Stock Chart
Analyst Coverage
Corporate Governance
Board of Directors
Committee Composition
Corporate Governance Documents
Information Request
Material Request
E-mail Alerts
RSS Feeds
Developing Best-in-Class Medicine. Improving Lives.
Recent News
July 24, 2020
|
Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain
July 16, 2020
|
Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI
®
for the Treatment of COVID-19
June 29, 2020
|
Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain
More News
Quick Links
Corporate Presentation
Pipeline
Scientific Posters and Presentations
